Incyte Corp - Company Profile
Powered by 
All the sales intelligence you need on Incyte Corp in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Incyte Corp fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Incyte Corp.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Incyte Corp (Incyte) is a biopharmaceutical company, that discovers, develops and commercializes proprietary cancer therapeutics. The company products portfolio includes JAKAFI, ICLUSIG, MONJUVI /MINJUVI and NIKTIMVO, as well as multiple clinical development programs. The company’s lead product, Jakafi (ruxolitinib) is marketed in the US for the treatment of patients with high-risk myelofibrosis; and polycythemia vera who are intolerant to hydroxyurea. The company distributes Jakafi through a network of specialty pharmacy providers and wholesalers. In collaboration with Incyte, Novartis International Pharmaceutical Ltd (Novartis) develops and commercializes ruxolitinib outside the US for hematologic and cancer indications under the name Jakavi. The company’s pipeline portfolio encompasses drugs for the treatment of lung cancer, graft versus host disease, b-cell malignancies, solid tumors, non-small cell lung cancer, liver cancer and malignancies. Incyte is headquartered in Wilmington, Delaware, the US.
Headquarters
United States of America
Address
1801 Augustine Cut-Off, Wilmington, Delaware, 19803
Website
www.incyte.com
Telephone
1 302 4986700
No of Employees
2,844
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
INCY (NASD)
Revenue (2024)
$5.1B
21.2%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
3845%
(2024 vs 2023)
Market Cap*
$22.7B
Net Profit Margin (2024)
XYZ
3,150.7%
(2024 vs 2023)
* As of and is in US$
Incyte Corp premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| - | - |
| Ponatinib | Jakafi |
| Ruxolitinib | Iclusig |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In June, the company entered into an agreement to acquire Vega Therapeutics, Inc. from Star Therapeutics, LLC for US$1.25 billion. |
| 2026 | Contracts/Agreements | In May, the company expanded their strategic collaboration with Genesis Molecular AI to build and deploy state-of-the-art AI to accelerate the discovery of novel molecules. |
| 2026 | Regulatory Approval | In May, the company received approval from the US FDA for Jakafi XR extended-release tablets. |
Competitor Comparison
| Key Parameters | Incyte Corp | Merck & Co Inc | Amgen Inc | Gilead Sciences Inc | Regeneron Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Wilmington | Rahway | Thousand Oaks | Foster City | Tarrytown |
| State/Province | Delaware | New Jersey | California | California | New York |
| No. of Employees | 2,844 | 75,000 | 31,500 | 17,000 | 15,410 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| William J. Meury | Chief Executive Officer; Director | Executive Board | 2025 | 57 |
| Suketu Upadhyay | Chief Financial Officer; Executive Vice President | Senior Management | 2026 | - |
| David Gardner | Chief Strategy Officer; Executive Vice President | Senior Management | 2025 | 43 |
| Steven H. Stein | Chief Medical Officer; Executive Vice President; Head - Late-stage Development | Senior Management | 2026 | - |
| Soni Basi | Chief Human Resources Officer; Executive Vice President | Senior Management | 2025 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer